ANNEX

In Annex VI to Regulation (EC) No 1272/2008, Table 3 of Part 3 is amended as follows:

* + 1. the following entries are inserted:

| **Index No** | **Chemical name** | **EC No** | **CAS No** | **Classification** | **Labelling** | **Specific Conc. Limits, M-factors and ATE** | **Notes** |
| --- | --- | --- | --- | --- | --- | --- | --- |
| **Hazard Class and Category Code(s)** | **Hazard statement Code(s)** | **Pictogram, Signal Word  Code(s)** | **Hazard statement Code(s)** | **Suppl. Hazard statement Code(s)** |
| ‘007-030-00-3 | nitric acid …% [C ≤ 70 %]  | 231-714-2 | 7697-3-2 | Ox. Liq. 3 Acute Tox. 3 Skin Corr. 1A | H272H331H314 | GHS03GHS06GHS05Dgr | H272H331H314 | EUH071 | Ox. Liq. 3; H272: C ≥ 65 %inhalation: ATE = 2.65 mg/L (vapours) Skin Corr. 1A; H314: C ≥ 20 %Skin Corr. 1B; H314: 5 % ≤ C <¶20 % | B’ |
| ‘014-048-00-5 | silicon carbide fibres (with diameter < 3 µm, length > 5 µm and aspect ratio ≥ 3:1) | 206-991-8 | 409-21-2308076-74-6 | Carc. 1B | H350i | GHS08Dgr | H350i’ |  |  |   |
| ‘014-049-00-0 | trimethoxyvinylsilane; trimethoxy(vinyl)silane | 220-449-8 | 2768-02-7 | Skin Sens. 1B | H317 | GHS07Wng | H317’ |  |  |   |
| ‘014-050-00-6 | tris(2-methoxyethoxy)vinylsilane; 6-(2-methoxyethoxy)-6-vinyl-2,5,7,10-tetraoxa-6-silaundecane | 213-934-0 | 1067-53-4 | Repr. 1B | H360FD | GHS08Dgr | H360FD’ |  |  |  |
| ‘016-098-00-3 | dimethyl disulphide | 210-871-0 | 624-92-0 | Flam. Liq. 2Acute Tox. 3Acute Tox. 3STOT SE 3STOT SE 1Eye Irrit. 2Skin Sens. 1Aquatic Acute 1Aquatic Chronic 1 | H225H331H301H370 (upper respiratory tract, inhalation)H319H317H400H410 | GHS02GHS06GHS08GHS09Dgr | H225H331H301H336H370 (upper respiratory tract, inhalation)H319H317H410 |  | inhalation: ATE = 5 mg/L (vapours)oral: ATE = 190 mg/kg bw¶M=1M=10’ |  |
| ‘029-024-00-X | granulated copper;[particle length: from 0.9 mm to 6.0 mm; particle width: from 0.494 to 0.949 mm]  | 231-159-6 | 7440-50-8 | Aquatic Chronic 2 | H411 | GHS09 | H411 |  |  |  |
| ‘029-025-00-5 | bis(*N*-hydroxy-*N*-nitrosocyclohexylaminato-*O*,*O*')copper; bis(*N*-cyclohexyl-diazenium-dioxy)-copper; [Cu-HDO] | 239-703-4 | 312600-89-815627-09-5 | Flam. Sol. 1Acute Tox. 4STOT RE 2Eye Dam. 1Aquatic Acute 1Aquatic Chronic 1 | H228H302H373 (liver)H318H400H410 | GHS02GHS07GHS08GHS05GHS09Dgr | H228H302H373 (liver)H318H410 |  | oral: ATE = 360 mg/kg bw¶M=1M=1’ |  |
| ‘050-031-00-9 | dioctyltin dilaurate; [1] stannane, dioctyl-, bis(coco acyloxy) derivs. [2] | 222-883-3 [1] 293-901-5 [2] | 3648-18-8 [1] 91648-39-4 [2] | Repr. 1BSTOT RE 1 | H360DH372 (immune system) | GHS08Dgr | H360DH372 (immune system)’ |  |  |  |
| ‘601-092-00-0 | dibenzo[*def*,*p*]chrysene;dibenzo[*a*,*l*]pyrene | 205-886-4 | 191-30-0 | Carc. 1BMuta. 2 | H350H341 | GHS08Dgr | H350H341 |  | Carc. 1B; H350: C ≥ 0,001 %’ |  |
| ‘603-237-00-3 | ipconazole (ISO);(1*RS*,2*SR*,5*RS*;1*RS*,2*SR*,5*SR*)-2-(4-chlorobenzyl)-5-isopropyl-1-(1*H*-1,2,4-triazol-1-ylmethyl)cyclopentanol | - | 125225-28-7115850-69-6115937-89-8 | Repr. 1BAcute Tox. 4STOT RE 2Aquatic Chronic 1 | H360DH302H373 (eyes, skin, liver)H410 | GHS08GHS07GHS09Dgr | H360DH302 H373 (eyes, skin, liver)H410 |  | oral: ATE = 500 mg/kg bw M=100’ |  |
| ‘603-238-00-9 | bis(2-(2-methoxyethoxy)ethyl)ether; tetraglyme | 205-594-7 | 143-24-8 | Repr. 1B | H360FD | GHS08Dgr | H360FD’ |  |  |  |
| ‘603-239-00-4 | paclobutrazol (ISO); (2*RS*,3*RS*)-1-(4-chlorophenyl)-4,4-dimethyl-2-(1*H*-1,2,4-triazol-1-yl)pentan-3-ol | - | 76738-62-0 | Repr. 2Acute Tox. 4Acute Tox. 4Eye Irrit. 2Aquatic Acute 1Aquatic Chronic 1 | H361dH332H302H319H400H410 | GHS08GHS07GHS09Wng | H361dH332H302H319H410 |  | inhalation: ATE = 3.13 mg/L (dusts or mists)oral: ATE = 490 mg/kg bwM=10M=10’ |  |
| ‘603-240-00-X | 2,2-bis(bromomethyl)propane-1,3-diol | 221-967-7 | 3296-90-0 | Carc. 1BMuta. 1B | H350H340 | GHS08 Dgr | H350H340’ |  |  |  |
| ‘603-241-00-5 | geraniol; (2*E*)-3,7-dimethylocta-2,6-dien-1-ol | 203-377-1 | 106-24-1 | Skin Sens. 1 | H317 | GHS07Wng | H317’ |  |  |  |
| ‘605-041-00-3 | 2-(4-*tert*-butylbenzyl)propionaldehyde | 201-289-8 | 80-54-6 | Repr. 1B | H360Fd | GHS08¶Dgr | H360Fd’ |  |  |  |
| ‘607-738-00-8 | MCPA-thioethyl (ISO); *S*-ethyl (4-chloro-2-methylphenoxy)ethanethioate; *S*-ethyl 4-chloro-*o*-tolyloxythioacetate | 246-831-4 | 25319-90-8 | Acute Tox. 4STOT RE. 2Aquatic Acute 1 Aquatic Chronic 1 | H302H373 (liver)H400H410 | GHS07GHS08GHS09Wng | H302H373 (liver)H410 |  | oral: ATE = 450 mg/kg bwM=10M=10’ |  |
| ‘607-740-00-9 | diisooctyl phthalate | 248-523-5 | 27554-26-3 | Repr. 1B | H360FD | GHS08Dgr | H360FD’ |  |  |  |
| ‘607-741-00-4 | 4-{[(6-chloropyridin-3-yl)methyl](2,2-difluoroethyl)amino}furan-2(5*H*)-one; flupyradifurone | - | 951659-40-8 | Acute Tox. 4STOT RE 2Aquatic Acute 1Aquatic Chronic 1 | H302H373 (muscle)H400H410 | GHS07GHS08GHS09Wng | H302H373 (muscle)H410 |  | oral: ATE = 500 mg/kg bwM=10M=10’ |  |
| ‘607-742-00-X | thiencarbazone-methyl (ISO); methyl 4-[(4,5-dihydro-3-methoxy-4-methyl-5-oxo-1*H*-1,2,4-triazol-1-yl)carbonylsulfamoyl]-5- methylthiophene-3-carboxylate | - | 317815-83-1 | Aquatic Acute 1Aquatic Chronic 1 | H400H410 | GHS09Wng | H410 |  | M=1000M=1000’ |  |
| ‘607-743-00-5 | L-(+)-lactic acid; (2*S*)-2-hydroxypropanoic acid | 201-196-2 | 79-33-4 | Skin Corr. 1C Eye Dam. 1 | H314H318 | GHS05Dgr | H314 | EUH071’ |  |  |
| ‘607-744-00-0 | 2-methoxyethyl acrylate | 221-499-3 | 3121-61-7 | Flam. Liq. 3Muta. 2Repr. 1BAcute Tox. 3Acute Tox. 4Skin Corr. 1CEye Dam. 1Skin Sens. 1 | H226H341H360FDH331H302H314H318H317 | GHS02GHS05GHS06GHS08Dgr | H226H341H360FDH331H302H314H317 | EUH071 | inhalation: ATE = 2.7 mg/L (vapours)oral: ATE = 404 mg/kg bw’ |  |
| ‘607-745-00-6 | glyoxylic acid …% | 206-058-5 | 298-12-4 | Eye Dam. 1Skin Sens. 1B | H318H317 | GHS05GHS07Dgr | H318H317 |  |  | B’ |
| ‘607-746-00-1 | sodium *N*-(hydroxymethyl)glycinate;[formaldehyde released from sodium *N*-(hydroxymethyl)glycinate] | 274-357-8 | 70161-44-3 | Carc. 1BMuta. 2Acute Tox. 4Acute Tox. 4 STOT SE 3Skin Irrit. 2Eye Irrit. 2Skin Sens. 1 | H350H341H332H302H335H315H319H317 | GHS08GHS07Dgr | H350H341H332H302H335H315H319H317 |  | inhalation: ATE = 3 mg/L (dusts or mists)oral: ATE = 1100 mg/kg bw | 89’ |
| ‘611-181-00-6 | potassium (oxido-*NNO*-azoxy)cyclohexane;cyclohexylhydroxydiazene 1-oxide, potassium salt; [K-HDO] | - | 66603-10-9 | Flam. Sol. 1Acute Tox. 3STOT RE 2Skin Irrit. 2Eye Dam. 1Aquatic Chronic 2 | H228H301H373 (liver)H315H318H411 | GHS02GHS06GHS08GHS05GHS09Dgr | H228H301H373 (liver)H315H318H411 |  | oral: ATE = 136 mg/kg bw’ |  |
| ‘612-294-00-3 | mecetronium etilsulfate; *N*-ethyl-*N*,*N*-dimethylhexadecan-1-aminium ethyl sulfate; mecetronium ethyl sulphate;[MES] | 221-106-5 | 3006-10-8 | Skin Corr. 1Eye Dam. 1Aquatic Acute 1Aquatic Chronic 1 | H314H318H400H410 | GHS05GHS09Dgr | H314H410 | EUH071 | M=100 M=1000’ |  |
| ‘613-331-00-6 | (2*RS*)-2-[4-(4-chlorophenoxy)-2-(trifluoromethyl)phenyl]-1-(1*H*-1,2,4-triazol-1-yl)propan-2-ol;mefentrifluconazole | - | 1417782-03-6 | Skin Sens. 1Aquatic Acute 1Aquatic Chronic 1 | H317H400H410 | GHS07GHS09Wng | H317H410 |  | M=1M=1’ |  |
| ‘613-332-00-1 | oxathiapiprolin (ISO); 1-(4-{4-[5-(2,6-difluorophenyl)-4,5-dihydro-1,2-oxazol-3-yl]-1,3-thiazol-2-yl}piperidin-1-yl)-2-[5-methyl-3-(trifluoromethyl)-1*H*-pyrazol-1-yl]ethanone | - | 1003318-67-9 | Aquatic Chronic 1 | H410 | GHS09Wng | H410 |  | M=1’ |  |
| ‘613-333-00-7 | pyrithione zinc; (*T*-4)-bis[1-(hydroxy-.kappa.*O*)pyridine-2(1*H*)-thionato-.kappa.*S*]zinc | 236-671-3 | 13463-41-7 | Repr. 1BAcute Tox. 2Acute Tox. 3STOT RE 1Eye Dam. 1Aquatic Acute 1Aquatic Chronic 1 | H360DH330H301H372H318H400H410 | GHS08GHS06GHS05GHS09Dgr | H360DH330H301H372H318H410 |  | inhalation: ATE = 0.14 mg/L (dusts or mists)oral: ATE = 221 mg/kg bwM=1000M=10’ |  |
| ‘613-334-00-2 | flurochloridone (ISO); 3-chloro-4-(chloromethyl)-1-[3-(trifluoromethyl)phenyl]pyrrolidin-2-one | 262-661-3 | 61213-25-0 | Repr. 1BAcute Tox. 4Skin Sens. 1Aquatic Acute 1 Aquatic Chronic 1 | H360FDH302H317H400H410 | GHS08GHS07GHS09Dgr | H360FDH302H317H410 |  | oral: ATE = 500 mg/kg bw¶M=100M=100’ |  |
| ‘613-335-00-8 | 4,5-dichloro-2-octyl-2*H*-isothiazol-3-one; [DCOIT] | 264-843-8 | 64359-81-5 | Acute Tox. 2Acute Tox. 4Skin Corr. 1Eye Dam. 1Skin Sens. 1AAquatic Acute 1Aquatic Chronic 1 | H330H302H314H318H317H400H410 | GHS06GHS05GHS09Dgr | H330H302H314H317H410 | EUH071 | inhalation: ATE = 0.16 mg/L (dusts or mists)oral: ATE = 567 mg/kg bwSkin Irrit. 2; H315: 0,025 % ≤ C < 5 % Eye Irrit. 2; H319: 0,025 % ≤ C < 3 %Skin Sens. 1A; H317: C ≥ 0,0015 %M=100M=100’ |  |
| ‘613-336-00-3 | 2-methyl-1,2-benzothiazol-3(2*H*)-one; [MBIT] | - | 2527-66-4 | Acute Tox. 4Acute Tox. 3Skin Corr. 1CEye Dam. 1Skin Sens. 1AAquatic Acute 1Aquatic Chronic 2 | H312H301H314H318H317H400H411 | GHS06GHS05GHS09Dgr | H312H301H314H317H410 | EUH071 | dermal: ATE = 1100 mg/kg bworal: ATE = 175 mg/kg bw Skin Sens. 1A; H317: C ≥ 0,0015 %M=1’ |  |
| ‘616-228-00-4 | 3-(difluoromethyl)-1-methyl-*N*-(3',4',5'-trifluorobiphenyl-2-yl)pyrazole-4-carboxamide; fluxapyroxad | - | 907204-31-3 | Lact.Aquatic Acute 1Aquatic Chronic 1 | H362H400H410 | GHS09Wng | H362H410 |  | M=1M=1’ |  |
| ‘616-230-00-5 | *N*-(hydroxymethyl)acrylamide; methylolacrylamide; [NMA] | 213-103-2 | 924-42-5 | Carc. 1B Muta. 1BSTOT RE 1 | H350H340H372 (peripheral nervous system) | GHS08Dgr | H350H340H372 (peripheral nervous system)’ |  |  |  |
| ‘616-231-00-0 | 5-fluoro-1,3-dimethyl-*N*-[2-(4-methylpentan-2-yl)phenyl]-1*H*-pyrazole-4-carboxamide; 2’-[(*RS*)-1,3-dimethylbutyl]-5-fluoro-1,3-dimethylpyrazole-4-carboxanilide; penflufen | - | 494793-67-8 | Carc. 2Aquatic Acute 1 Aquatic Chronic 1 | H351H400H410 | GHS08GHS09Wng | H351 H410 |  | M=1M=1’ |  |
| ‘616-232-00-6 | iprovalicarb (ISO); isopropyl [(2*S*)-3-methyl-1-{[1-(4-methylphenyl)ethyl]amino}-1-oxobutan-2-yl]carbamate | - | 140923-17-7 | Carc. 2 | H351 | GHS08Wng | H351’ |  |  |  |
| ‘616-233-00-1 | silthiofam (ISO); *N*-allyl-4,5-dimethyl-2-(trimethylsilyl)thiophene-3-carboxamide | - | 175217-20-6 | STOT RE 2Aquatic Chronic 2 | H373H411 | GHS08GHS09Wng | H373H411’ |  |  |  |
| ‘650-057-00-6 | Margosa, ext. [cold-pressed oil of *Azadirachta indica* seeds without shells extracted with super-critical carbon dioxide] | 283-644-7 | 84696-25-3 | Aquatic Chronic 3 | H412 |  | H412’ |  |  | ; |

* + 1. the entries corresponding to index numbers 007-004-00-1; 014-018-00-1; 015-134-00-5; 015-181-00-1; 050-021-00-4; 050-027-00-7; 082-013-00-1; 082-014-00-7; 603-014-00-0; 603-065-00-9; 605-019-00-3; 607-177-00-9; 607-256-00-8; 607-314-00-2; 609-041-00-4; 609-064-00-X; 613-112-00-5; 613-115-00-1; 613-125-00-6; 613-202-00-4; 613-259-00-5; 616-014-00-0 and 617-006-00-X are replaced by the following entries respectively:

| **Index No** | **Chemical name** | **EC No** | **CAS No** | **Classification** | **Labelling** | **Specific Conc. Limits, M-factors and ATE** | **Notes** |
| --- | --- | --- | --- | --- | --- | --- | --- |
| **Hazard Class and Category Code(s)** | **Hazard statement Code(s)** | **Pictogram, Signal Word  Code(s)** | **Hazard statement Code(s)** | **Suppl. Hazard statement Code(s)** |
| ‘007-004-00-1 | nitric acid …% [C > 70 %] | 231-714-2 | 7697-37-2 | Ox. Liq. 2Acute Tox. 1Skin Corr. 1A | H272H330H314 | GHS03GHS06GHS05Dgr | H272H330H314 | EUH071 | Ox. Liq. 2; H272: C ≥ 99 % Ox. Liq. 3; H272: 70 % ≤ C < 99 % | B’ |
| ‘014-018-00-1 | octamethylcyclotetrasiloxane; [D4] | 209-136-7 | 556-67-2 | Repr. 2Aquatic Chronic 1 | H361f \*\*\*H410 | GHS08GHS09Wng | H361f \*\*\*H410 |  | M=10’ |  |
| ‘015-134-00-5 | pirimiphos-methyl (ISO); *O*-[2-(diethylamino)-6-methylpyrimidin-4-yl] *O*,*O*-dimethyl phosphorothioate | 249-528-5 | 29232-93-7 | Acute Tox. 4STOT RE 1Aquatic Acute 1Aquatic Chronic 1 | H302H372 (nervous system)H400H410 | GHS07GHS08GHS09Dgr  | H302H372 (nervous system)H410 |  | oral: ATE = 1414 mg/kg bwM=1000M=1000’ |  |
| ‘015-181-00-1 | phosphine | 232-260-8 | 7803-51-2 | Flam. Gas 1Press. GasAcute Tox. 1Skin Corr. 1BAquatic Acute 1 | H220H330H314H400 | GHS02GHS04GHS06GHS05GHS09Dgr | H220H330H314H400 |  | inhalation:ATE = 10 ppmV (gases) | U’ |
| ‘050-021-00-4 | dichlorodioctylstannane | 222-583-2 | 3542-36-7 | Repr. 1BAcute Tox. 2STOT RE 1Aquatic Chronic 3 | H360DH330H372 \*\*H412 | GHS08GHS06Dgr | H360D H330H372 \*\*H412 |  | Repr. 1B; H360 D: C ≥ 0,03 %inhalation: ATE = 0.098 mg/L (dusts or mists)’ |  |
| ‘050-027-00-7 | 2-ethylhexyl 10-ethyl-4,4-dioctyl-7-oxo-8-oxa-3,5-dithia-4-stannatetradecanoate; [DOTE] | 239-622-4 | 15571-58-1 | Repr. 1BSTOT RE 1Aquatic Acute 1Aquatic Chronic 1 | H360DH372 (immune system)H400H410 | GHS08GHS09Dgr | H360DH372 (immune system)H410‘ |  |  |  |
| ‘082-013-00-1 | lead powder; ¶[particle diameter < 1 mm] | 231-100-4 | 7439-92-1 | Repr. 1ALact.Aquatic Acute 1 Aquatic Chronic 1 | H360FD H362H400H410 | GHS08GHS09Dgr | H360FD H362H410 |  | Repr. 1A; H360D: C ≥ 0,03 %M=1M=10’ |  |
| ‘082-014-00-7 | lead massive; [particle diameter ≥ 1 mm] | 231-100-4 | 7439-92-1 | Repr. 1ALact.Aquatic Acute 1Aquatic Chronic 1 | H360FD H362H400H410 | GHS08GHS09Dgr | H360FD H362H410 |  | M=1M=10’ |  |
| ‘603-014-00-0 | 2-butoxyethanol; ethylene glycol monobutyl ether | 203-905-0 | 111-76-2 | Acute Tox. 3Acute Tox. 4Skin Irrit. 2Eye Irrit. 2 | H331H302H315H319 | GHS06Dgr | H331H302H315H319 |  | inhalation: ATE = 3 mg/L (vapours)¶oral: ATE = 1200 mg/kg bw’ |  |
| ‘603-065-00-9 | *m*-bis(2,3-epoxypropoxy)benzene; resorcinol diglycidyl ether | 202-987-5 | 101-90-6 | Carc. 1B¶Muta. 2¶Acute Tox. 3Acute Tox. 4Skin Irrit. 2Eye Irrit. 2Skin Sens. 1Aquatic Chronic 3  | H350H341H311H302H315H319H317H412 | GHS08GHS06Dgr | H350H341H311H302H315H319H317H412 |  | dermal: ATE = 300 mg/kg bw oral: ATE = 500 mg/kg bw¶’ |  |
| ‘607-177-00-9  | tribenuron-methyl (ISO); methyl 2-[*N*-(4-methoxy-6-methyl-1,3,5-triazin-2-yl)-*N*-methylcarbamoylsulfamoyl]benzoate | 401-190-1 | 101200-48-0 | STOT RE 2Skin Sens. 1Aquatic Acute 1Aquatic Chronic 1 | H373H317H400H410 | GHS08GHS07 GHS09 Wng | H373H317H410 |  | M=100 M=100 ‘ |  |
| ‘607-256-00-8 | azoxystrobin (ISO); methyl (*E*)-2-{2-[6-(2-cyanophenoxy)pyrimidin-4-yloxy]phenyl}-3-methoxyacrylate | - | 131860-33-8 | Acute Tox. 3Aquatic Acute 1Aquatic Chronic 1 | H331H400H410 | GHS06GHS09Dgr | H331H410 |  | inhalation:ATE = 0.7 mg/L (dusts or mists)M=10M=10’ |  |
| ‘607-314-00-2 | ethofumesate (ISO); (*RS*)-2-ethoxy-2,3-dihydro-3,3-dimethylbenzofuran-5-yl methanesulfonate | 247-525-3 | 26225-79-6 | Aquatic Acute 1Aquatic Chronic 1 | H400H410 | GHS09Wng | H410 |  | M=1M=1 ‘  |  |
| ‘609-041-00-4 | 2,4-dinitrophenol | 200-087-7 | 51-28-5 | Acute Tox. 3 \*Acute Tox. 3Acute Tox. 2STOT RE 1Aquatic Acute 1  | H331H311H300 H372H400 | GHS06 GHS08 GHS09Dgr  | H331H311H300H372H400 |  | dermal: ATE = 300 mg/kg bw oral: ATE = 30 mg/kg bw’ |   |
| ‘609-064-00-X | mesotrione (ISO); 2-[4-(methylsulfonyl)-2-nitrobenzoyl]-1,3-cyclohexanedione | - | 104206-82-8 | Repr. 2STOT RE 2 Aquatic Acute 1Aquatic Chronic 1 | H361dH373 (eyes, nervous system)H400H410 | GHS08GHS09Wng | H361dH373 (eyes, nervous system)H410 |  | M=10M=10’ |   |
| ‘613-112-00-5 | octhilinone (ISO); 2-octyl-2*H*-isothiazol-3-one; [OIT] | 247-761-7 | 26530-20-1 | Acute Tox. 2Acute Tox. 3Acute Tox. 3Skin Corr. 1Eye Dam. 1Skin Sens. 1AAquatic Acute 1 Aquatic Chronic 1 | H330H311H301H314H318H317H400H410 | GHS06GHS05GHS09Dgr | H330H311H301H314H317H410 | EUH071 | inhalation: ATE = 0.27 mg/L (dusts or mists)dermal: ATE = 311 mg/kg bw oral: ATE = 125 mg/kg bwSkin Sens. 1A; H317: C ≥ 0,0015 %M=100M=100’ |   |
| ‘613-115-00-1 | hymexazol (ISO); 3-hydroxy-5-methylisoxazole | 233-000-6 | 10004-44-1 | Repr. 2Acute Tox. 4Eye Dam. 1Skin Sens. 1 Aquatic Chronic 2 | H361dH302H318H317H411 | GHS08GHS07GHS05GHS09Dgr | H361dH302H318H317H411 |  | oral: ATE = 1600 mg/kg bw’ |   |
| ‘613-125-00-6 | hexythiazox (ISO); *trans*-5-(4-chlorophenyl)-*N*-cyclohexyl-4-methyl-2-oxo-3-thiazolidine-carboxamide | - | 78587-05-0 | Aquatic Acute 1Aquatic Chronic 1 | H400H410 | GHS09Wng | H410 |  | M=1M=1’ |   |
| ‘613-202-00-4 | pymetrozine (ISO); (*E*)-4,5-dihydro-6-methyl-4-(3-pyridylmethyleneamino)-1,2,4-triazin-3(2*H*)-one | - | 123312-89-0 | Carc. 2 Repr. 2Aquatic Chronic 1 | H351H361fdH410 | GHS08GHS09Wng | H351H361fdH410 |  | M=1’ |   |
| ‘613-259-00-5 | imiprothrin (ISO); reaction mass of: [2,4-dioxo-(2-propyn-1-yl)imidazolidin-3-yl]methyl(1*R*)-*cis*-chrysanthemate; [2,4-dioxo-(2-propyn-1-yl)imidazolidin-3-yl]methyl(1*R*)-*trans*-chrysanthemate | 428-790-6 | 72963-72-5 | Carc. 2Acute Tox. 4 Acute Tox. 4STOT SE 2Aquatic Acute 1Aquatic Chronic 1 | H351H332H302H371 (nervous system; oral, inhalation)¶H400H410 | GHS08GHS07GHS09Wng | H351H332H302H371 (nervous system; oral, inhalation)H410 |  | inhalation: ATE = 1.4 mg/L (dusts or mists)oral: ATE = 550 mg/kg bwM=10M=10 ‘ |   |
| ‘616-014-00-0 | butanone oxime; ¶ethyl methyl ketoxime; ¶ethyl methyl ketone oxime | 202-496-6 | 96-29-7 | Carc. 1BAcute Tox. 4Acute Tox. 3STOT SE 3STOT SE 1STOT RE 2 Skin Irrit. 2Eye Dam. 1 Skin Sens. 1¶ | H350 H312H301 H336H370 (upper respiratory tract)H373 (blood system)H315H318H317 ¶ | GHS08GHS06¶GHS05Dgr | H350 H312¶H301 H336H370 (upper respiratory tract)¶H373 (blood system)H315H318 H317 |  | dermal: ATE = 1100 mg/kg bw oral: ATE = 100 mg/kg bw’ |   |
| ‘617-006-00-X | bis(α,α-dimethylbenzyl) peroxide | 201-279-3 | 80-43-3 | Org. Perox. FRepr. 1BSkin Irrit. 2Eye Irrit. 2Aquatic Chronic 2 | H242H360DH315H319H411 | GHS02GHS08GHS07GHS09Dgr | H242H360D¶H315H319H411’ |  |  | ; |

* + 1. the entries corresponding to index numbers 601-064-00-8 and 607-693-00-4 are deleted.